MG
ALLO icon

Michael Gelband’s Allogene Therapeutics ALLO Stock Holding History

Michael Gelband’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-64,313
Closed -$157K – 1533
2026
Q1 		$157K Buy
+64,313
New +$129K ﹤0.01% 1405
2024
Q4 		– Sell
-1,634,838
Closed -$4.58M – 1471
2024
Q3 		$4.58M Buy
1,634,838
+1,343,724
+462% +$3.58M 0.03% 456
2024
Q2 		$678K Buy
291,114
+128,091
+79% +$378K ﹤0.01% 1139
2024
Q1 		$729K Sell
163,023
-299,804
-65% -$1.25M 0.01% 1042
2023
Q4 		$1.49M Buy
462,827
+352,837
+321% +$1M 0.01% 670
2023
Q3 		$349K Sell
109,990
-317,762
-74% -$1.39M ﹤0.01% 1369
2023
Q2 		$2.13M Sell
427,752
-247,527
-37% -$1.34M 0.02% 783
2023
Q1 		$3.34M Sell
675,279
-483,422
-42% -$3.1M 0.03% 672
2022
Q4 		$7.29M Buy
1,158,701
+935,460
+419% +$8.66M 0.11% 253
2022
Q3 		$2.41M Buy
223,241
+192,738
+632% +$2.62M 0.03% 708
2022
Q2 		$348K Sell
30,503
-18,857
-38% -$167K ﹤0.01% 1479
2022
Q1 		$450K Sell
49,360
-84,940
-63% -$885K 0.01% 1594
2021
Q4 		$2M Buy
+134,300
New +$2.37M 0.02% 760
2021
Q3 		– Sell
-12,475
Closed -$325K – 2062
2021
Q2 		$325K Buy
12,475
+1,941
+18% +$55.4K ﹤0.01% 1688
2021
Q1 		$372K Buy
+10,534
New +$355K 0.01% 1536

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Michael Gelband's ALLO Position: Q2 2026 in Review

Michael Gelband sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 64,313 shares — an estimated $157K sold.

Michael Gelband first reported a position in ALLO in Q1 2021 and held it in 15 quarters. The position peaked at $7.29M in Q4 2022. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Michael Gelband reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 64,313 Allogene Therapeutics shares in Q2 2026, an estimated $157K.
  • Michael Gelband first reported a position in Allogene Therapeutics in Q1 2021 and held it in 15 quarters.
  • Michael Gelband's Allogene Therapeutics position peaked at $7.29M in Q4 2022.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.